4//SEC Filing
JANNEY DANIEL 4
Accession 0000899243-21-036429
CIK 0001863127other
Filed
Sep 16, 8:00 PM ET
Accepted
Sep 17, 4:47 PM ET
Size
17.2 KB
Accession
0000899243-21-036429
Insider Transaction Report
Form 4
Transactions
- Conversion
Series B Preferred Stock
2021-09-17−255,160→ 0 total(indirect: See footnote)→ Common Stock (662,752 underlying) - Purchase
Common Stock
2021-09-17$16.00/sh+156,250$2,500,000→ 4,080,296 total(indirect: See footnote) - Conversion
Common Stock
2021-09-17+3,811,117→ 3,924,046 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2021-09-17−1,212,122→ 0 total(indirect: See footnote)→ Common Stock (3,148,365 underlying)
JANNEY DANIEL
10% Owner
Transactions
- Conversion
Common Stock
2021-09-17+3,811,117→ 3,924,046 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2021-09-17−1,212,122→ 0 total(indirect: See footnote)→ Common Stock (3,148,365 underlying) - Purchase
Common Stock
2021-09-17$16.00/sh+156,250$2,500,000→ 4,080,296 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2021-09-17−255,160→ 0 total(indirect: See footnote)→ Common Stock (662,752 underlying)
Alta Partners NextGen Fund II, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2021-09-17+3,811,117→ 3,924,046 total(indirect: See footnote) - Purchase
Common Stock
2021-09-17$16.00/sh+156,250$2,500,000→ 4,080,296 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2021-09-17−255,160→ 0 total(indirect: See footnote)→ Common Stock (662,752 underlying) - Conversion
Series A Preferred Stock
2021-09-17−1,212,122→ 0 total(indirect: See footnote)→ Common Stock (3,148,365 underlying)
Hudson Peter A
10% Owner
Transactions
- Purchase
Common Stock
2021-09-17$16.00/sh+156,250$2,500,000→ 4,080,296 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2021-09-17−255,160→ 0 total(indirect: See footnote)→ Common Stock (662,752 underlying) - Conversion
Common Stock
2021-09-17+3,811,117→ 3,924,046 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2021-09-17−1,212,122→ 0 total(indirect: See footnote)→ Common Stock (3,148,365 underlying)
Footnotes (2)
- [F1]On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. As a result of the Issuer's initial public offering, the reporting persons are no longer 10% owners of the Issuer's common stock and are, therefore, no longer subject to Section 16 in connection with their transactions in the equity securities of the Issuer.
- [F2]These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The shares directly held by APNG II are indirectly held by Alta Partners NextGen Fund II Management, LLC ("APNG II Management"), which is the general partner of APNG II. The individual managing directors of APNG II Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG II Management exercise shared voting and investment control with respect to the shares held by APNG II. APNG II Management, Mr. Hudson and Mr. Janney disclaim beneficial ownership of all shares held by APNG II, except to the extent of its or their respective pecuniary interests therein. Mr. More is a director of the Issuer and files separate Section 16 reports.
Documents
Issuer
Tyra Biosciences, Inc.
CIK 0001863127
Entity typeother
Related Parties
1- filerCIK 0001198325
Filing Metadata
- Form type
- 4
- Filed
- Sep 16, 8:00 PM ET
- Accepted
- Sep 17, 4:47 PM ET
- Size
- 17.2 KB